Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for ...

Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

Early results of Eli Lilly’s next generation of weight loss drugs appear to show promise, possibly leading to even faster ...

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...

Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to ...

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...

Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...

Eli Lilly and Novo Nordisk have become the latest pharma giants to strike price-reduction deals with the White House, agreeing to sell their weight loss drugs at cut-rate prices to patients in the U.S ...

According to the White House, Novo Nordisk's semaglutide-based Ozempic for diabetes and Wegovy for obesity will cost $350 per ...

The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst ...

Eli Lilly’s anti-obesity and diabetes drug Mounjaro has become the No. 1 brand by sales value in the Indian Pharmaceutical ...